Summary

The 7 major meibomian gland dysfunction markets reached a value of US$ 2.1 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 4.5 Billion by 2034, exhibiting a growth rate (CAGR) of 7.07% during 2024-2034.

The meibomian gland dysfunction market has been comprehensively analyzed in IMARC's new report titled "Meibomian Gland Dysfunction Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Meibomian gland dysfunction (MGD) refers to a set of diseases that can be either congenital or acquired and are connected by functional deviations of the meibomian glands. This condition develops when one of the several dozen small glands in the eyelids that contribute to the production of the oil layer in tears has a problem. The ailment can cause a change in the composition of the tear film, ocular surface disease, discomfort in the eyes and eyelids, and evaporative dry eye. Based on gland secretion, MGD can be classified as low or high delivery. There are no specific indications in the early stages, but as the condition progresses, the patients may experience less or poor-quality oil in the tear film, irritated, inflamed, and itchy eyelids, a feeling of sand or dust in the eye, stickiness or crusting, moments of blurred vision, burning sensations, etc. The diagnosis of this ailment is made by a review of underlying symptoms, medical history, and an initial clinical examination. Various other common procedures to confirm a diagnosis include Schirmer's test, mass spectrometry, interferometry, etc.

The rising cases of eye diseases, which cause damage and inflammation to the eyelids and cornea, are primarily driving the meibomian gland dysfunction market. Additionally, the increasing prevalence of various risk factors, such as hormonal changes, allergies, skin conditions, use of eye makeup, contact lens wear, etc., are further propelling the market growth. Moreover, the widespread adoption of effective drugs, including antibiotics, steroids, omega-3 fatty acid supplements, etc., to help reduce indications associated with the ailment is acting as another significant growth-inducing factor. Apart from this, the rising usage of non-pharmacological interventions, such as warm compresses and massage therapy, since they can ease irritation and open clogged oil glands, is also augmenting the market growth. Furthermore, the escalating demand for non-contact meibography, owing to its numerous advantages over traditional meibography, including lesser time consumption, reduced risk of infection, and minimum patient discomfort, is creating a positive outlook for the market. Besides this, the increasing utilization of vector thermal pulsation system that delivers regulated amounts of pressure and heat to clear blockages in the meibomian glands for disease management is expected to drive the meibomian gland dysfunction market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the meibomian gland dysfunction market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for meibomian gland dysfunction and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the meibomian gland dysfunction market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the meibomian gland dysfunction market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the meibomian gland dysfunction market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current meibomian gland dysfunction marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the meibomian gland dysfunction market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the meibomian gland dysfunction market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the meibomian gland dysfunction market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (​2018-2034​) of meibomian gland dysfunction across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of meibomian gland dysfunction by age across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of meibomian gland dysfunction by gender across the seven major markets?
How many patients are diagnosed (​2018-2034​) with meibomian gland dysfunction across the seven major markets?
What is the size of the meibomian gland dysfunction patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of meibomian gland dysfunction?
What will be the growth rate of patients across the seven major markets?

Meibomian Gland Dysfunction: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for meibomian gland dysfunction drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the meibomian gland dysfunction market?
What are the key regulatory events related to the meibomian gland dysfunction market?
What is the structure of clinical trial landscape by status related to the meibomian gland dysfunction market?
What is the structure of clinical trial landscape by phase related to the meibomian gland dysfunction market?
What is the structure of clinical trial landscape by route of administration related to the meibomian gland dysfunction market?

ページTOPに戻る

Table of Contents

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Meibomian Gland Dysfunction - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 Meibomian Gland Dysfunction - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Meibomian Gland Dysfunction - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (​2018-2034​)
7.2.4 Epidemiology by Gender (​2018-2034​)
7.2.5 Diagnosed Cases (​2018-2034​)
7.2.6 Patient Pool/Treated Cases (​2018-2034​)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (​2018-2034​)
7.3.4 Epidemiology by Gender (​2018-2034​)
7.3.5 Diagnosed Cases (​2018-2034​)
7.3.6 Patient Pool/Treated Cases (​2018-2034​)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (​2018-2034​)
7.4.4 Epidemiology by Gender (​2018-2034​)
7.4.5 Diagnosed Cases (​2018-2034​)
7.4.6 Patient Pool/Treated Cases (​2018-2034​)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (​2018-2034​)
7.5.4 Epidemiology by Gender (​2018-2034​)
7.5.5 Diagnosed Cases (​2018-2034​)
7.5.6 Patient Pool/Treated Cases (​2018-2034​)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (​2018-2034​)
7.6.4 Epidemiology by Gender (​2018-2034​)
7.6.5 Diagnosed Cases (​2018-2034​)
7.6.6 Patient Pool/Treated Cases (​2018-2034​)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (​2018-2034​)
7.7.4 Epidemiology by Gender (​2018-2034​)
7.7.5 Diagnosed Cases (​2018-2034​)
7.7.6 Patient Pool/Treated Cases (​2018-2034​)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (​2018-2034​)
7.8.4 Epidemiology by Gender (​2018-2034​)
7.8.5 Diagnosed Cases (​2018-2034​)
7.8.6 Patient Pool/Treated Cases (​2018-2034​)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (​2018-2034​)
7.9.4 Epidemiology by Gender (​2018-2034​)
7.9.5 Diagnosed Cases (​2018-2034​)
7.9.6 Patient Pool/Treated Cases (​2018-2034​)

8 Meibomian Gland Dysfunction - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Meibomian Gland Dysfunction - Unmet Needs

10 Meibomian Gland Dysfunction - Key Endpoints of Treatment

11 Meibomian Gland Dysfunction - Marketed Products
11.1 List of Meibomian Gland Dysfunction Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 Meibomian Gland Dysfunction - Pipeline Drugs
12.1 List of Meibomian Gland Dysfunction Pipeline Drugs Across the Top 7 Markets
12.1.1 AZR MD 001 - Azura Ophthalmics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 CBT008 - Cloudbreak therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 CBT006 - Cloudbreak therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. Meibomian Gland Dysfunction - Attribute Analysis of Key Marketed and Pipeline Drugs

14. Meibomian Gland Dysfunction – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Meibomian Gland Dysfunction - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Meibomian Gland Dysfunction - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Meibomian Gland Dysfunction - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Meibomian Gland Dysfunction - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Meibomian Gland Dysfunction - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Meibomian Gland Dysfunction - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Meibomian Gland Dysfunction - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Meibomian Gland Dysfunction - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Meibomian Gland Dysfunction - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Meibomian Gland Dysfunction - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Meibomian Gland Dysfunction - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Meibomian Gland Dysfunction - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Meibomian Gland Dysfunction - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Meibomian Gland Dysfunction - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Meibomian Gland Dysfunction - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Meibomian Gland Dysfunction - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Meibomian Gland Dysfunction - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Meibomian Gland Dysfunction - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Meibomian Gland Dysfunction - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Meibomian Gland Dysfunction - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Meibomian Gland Dysfunction - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Meibomian Gland Dysfunction - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Meibomian Gland Dysfunction - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Meibomian Gland Dysfunction - Access and Reimbursement Overview

16 Meibomian Gland Dysfunction - Recent Events and Inputs From Key Opinion Leaders

17 Meibomian Gland Dysfunction Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Meibomian Gland Dysfunction Market – Strategic Recommendations

19 Appendix